Generic Pharmaceutical Antitrust Settlements

Approximately $533M in settlement funds have been reached to date.

If your organization purchased, paid for or reimbursed the cost of certain prescription generic drugs in the United States between May 1, 2009 and December 31, 2019, it may be eligible to submit a claim in settlements reached in the In re Generic Pharmaceuticals Pricing Antitrust Litigation.

Eligibility depends on several factors, including the drugs purchased, where the purchases were made, how the purchases were funded and whether your organization falls within one of the Settlement Class exclusions. The $533 million represents several separate settlements and is not necessarily a single pool available to Third Party Payers.

About the Litigation

The litigation consists of coordinated class actions pending in the United States District Court for the Eastern District of Pennsylvania under the caption: In re Generic Pharmaceuticals Pricing Antitrust Litigation, Case No. 2:16-MD-2724-CMR.

End-Payer Plaintiffs allege that certain generic pharmaceutical manufacturers conspired to fix, maintain, stabilize or raise the prices of certain prescription generic drugs, allocate customers or markets, and engage in other conduct that violated federal and state antitrust and consumer-protection laws. The defendants have denied the allegations and denied liability. The Court has not decided the claims against the remaining Non-Settling Defendants. Several defendants have entered into settlements without admitting wrongdoing.

What the Lawsuit Alleges

The End-Payer Plaintiffs allege that certain pharmaceutical manufacturers coordinated pricing and other commercial activity in violation of federal and state antitrust laws.

According to the allegations, this conduct caused consumers and Third-Party Payers to pay more for certain generic prescription drugs than they would have paid in a competitive market.

These remain allegations.

The Settling Defendants deny liability, and settlements do not constitute an admission of wrongdoing.

Who May be Eligible

The Court has certified or approved Settlement Classes for settlement purposes.

You may be a Settlement Class Member if you are a consumer or Third-Party Payer that indirectly purchased, paid for or reimbursed some or all of the purchase price of one or more Named Generic Drugs:

In the United States, except Indiana and Ohio, or in the District of Columbia, Puerto Rico or the U.S. Virgin Islands;
Between May 1, 2009 and December 31, 2019;
For personal use by you or your members; and
Other than for resale.

Third-Party Payers may include certain self-funded health plans, employee benefit plans, health and welfare funds, insurers and other entities that reimbursed eligible prescription drug costs.

The Settlement Classes contain specific exclusions. These include certain governmental entities, defendants and their related parties, purchases made directly from defendants, purchases made for resale, fully insured employers to the extent they used fully insured plans, and pharmacy benefit managers.

The Named Generic Drugs and complete Settlement Class definitions are available through the official settlement website.

Eligibility is determined under the Court-approved settlement documents. Receiving notice of the settlements, or meeting the general description above, does not guarantee that a claimant is eligible or will receive payment.

Sandoz and Fougera Settlement

Sandoz Inc. and Fougera Pharmaceuticals Inc. agreed to establish a settlement fund of approximately $275 million to resolve End-Payer claims.

The settlement does not constitute an admission of liability or wrongdoing.

Apotex and Heritage Settlements

Apotex Corp. agreed to establish a settlement fund of approximately $48 million. Heritage Pharmaceuticals Inc. and related defendants agreed to establish a settlement fund of approximately $10 million.

These settlements resolve certain End-Payer claims against the settling parties and do not constitute admissions of liability or wrongdoing.

Sun and Taro Settlement

Sun Pharmaceutical Industries and Taro Pharmaceutical Industries agreed to establish a settlement fund of approximately $200 million to resolve certain End-Payer claims.

The settlement does not constitute an admission of liability or wrongdoing.

Settlement funds may be reduced by Court-approved attorneys’ fees, litigation expenses, settlement administration costs, service awards and any other deductions authorized by the Court. Payments to eligible claimants will depend on the applicable allocation plans, qualifying purchases, supporting data, the number and value of valid claims submitted, Court orders and other factors.

No particular recovery amount is guaranteed. The current claims process applies to the settlements involving the settling defendants identified above. The broader litigation remains ongoing against other defendants that are not part of these settlements.

Important settlement and claims filing disclosure

Biz Head Law is an independent law firm providing legal and claims management services and is not affiliated with or appointed by the Court, the Claims Administrator, or Settlement Class Counsel. The current claims filing deadline is November 9, 2026. You do not need to retain Biz Head Law or another third party service provider to submit a claim or pay a percentage of your settlement recovery to participate. Eligible claimants may submit claims directly through the Claims Administrator at no cost, and free assistance is available from the Claims Administrator and Settlement Class Counsel. For official settlement information, Court approved notices, claim forms, filing instructions, eligible drug lists, settlement documents, and current deadlines, please visit www.GenericDrugsEndPayerSettlement.com. The Claims Administrator can be contacted at 1-877-316-0171 or info@GenericDrugsEndPayerSettlement.com. Settlement Class Counsel, Roberta D. Liebenberg of Fine, Kaplan and Black, R.P.C., can be contacted at (215) 567-6565 or rliebenberg@finekaplan.com.

Preliminary Eligibility Review

We review your organization’s information against the applicable Settlement Class requirements.

Data and Document Review

We help identify and organize available pharmacy, reimbursement, benefits and payment records that may support the claim.

Claim Preparation and Filing

Together with our co-counsel, we support preparation of the required claim information and supporting materials.

Submission Support

We keep you updated on the submission process and address any questions relating to the claim along the way.

Claim Follow-Up

Where appropriate, we help monitor the claim and respond to requests from the Claims Administrator.

Recovery Admin

If a claim is approved and funds are distributed, we help your organization review the payment and complete the recovery process.

Working with BizHead Law has been a great experience and they have been patient with us at every step. We're a small business and I think it means a lot that they treated us like anyone of their larger clients. They made sure we felt comfortable and well informed by explaining the what and why we are doing things. Thanks for the help guys!

Tyler D (Google Review)

Biz Head Law Client

Representation you can depend on.

Experience With Complex Business Claims - BHL works with organizations that may have years of reimbursement records, changing benefits arrangements and data held across several systems or vendors.

A Managed Filing Process - We help coordinate the records, calculations, documentation and submission requirements involved in preparing a claim.

Performance-Based Fee - Subject to the terms of your written agreement with BHL, fees are contingent on recovery. The applicable fee and all client obligations are stated in the Claim Filing Agreement.

Clients may instead file directly with the Court-appointed Claims Administrator at no cost.